Wang Si-Tien, Johnson Scott J, Mitchell Dominic, Soliman Ahmed M, Vora Jamie B, Agarwal Sanjay K
Medicus Economics LLC, Milton, MA 02186, USA.
AbbVie, Inc., North Chicago, IL 60064, USA.
J Comp Eff Res. 2019 Apr;8(5):337-355. doi: 10.2217/cer-2018-0124. Epub 2019 Feb 6.
To assess the cost-effectiveness of elagolix versus leuprolide acetate in women with moderate to severe endometriosis pain.
A Markov model was developed. The efficacy of leuprolide acetate was derived from statistical prediction models using elagolix trial data. Model inputs were extracted from Phase III clinical trials and published literature.
Compared with leuprolide acetate, elagolix generated positive net monetary benefit (NMB) assuming a payer's willingness-to-pay threshold of US$100,000 per quality-adjusted life year over a 1-year time horizon: US$5660 for elagolix 150 mg and US$6443 for elagolix 200 mg. The 2-year NMBs were also positive.
Elagolix was cost effective versus leuprolide acetate in the management of moderate to severe endometriosis pain over 1- and 2-year time horizons. Results were robust in sensitivity analyses.
评估艾拉戈利与醋酸亮丙瑞林治疗中重度子宫内膜异位症疼痛的成本效益。
建立了一个马尔可夫模型。醋酸亮丙瑞林的疗效来自于使用艾拉戈利试验数据的统计预测模型。模型输入数据从III期临床试验和已发表的文献中提取。
与醋酸亮丙瑞林相比，假设支付者每质量调整生命年的支付意愿阈值为100,000美元，在1年时间范围内，艾拉戈利产生了正的净货币效益（NMB）：150mg艾拉戈利为5660美元，200mg艾拉戈利为6443美元。2年的NMB也是正的。
在1年和2年时间范围内，艾拉戈利在治疗中重度子宫内膜异位症疼痛方面比醋酸亮丙瑞林更具成本效益。敏感性分析结果稳健。
